Javier Blesa

Dr. Javier Blesa

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2015 in Frontiers in Neuroanatomy
Verified
Journal Article
Open access
PDF file
JBJavier Blesa
Javier Blesa
ITInes Trigo-Damas
Ines Trigo-Damas
AQAnna Quiroga-Varela
Anna Quiroga-Varela
VJVernice R. Jackson-Lewis
Vernice R. Jackson-Lewis
Parkinson disease is a chronic, progressive neurological disease that is associated with a loss of dopaminergic neurons in the substantia nigra of the brain. The molecular mechanisms underlying the loss of these neurons still remain elusive. Oxidative stress is thought to play an important role in dopaminergic neurotoxicity. Complex I deficiencies of the respiratory chain account for the majority of unfavorable neuronal degeneration in Parkinson’s Disease. Environmental factors, such as neurotoxins, insecticides like rotenone, pesticides like Paraquat, dopamine itself and genetic mutations in Parkinson’s Disease related proteins contribute to mitochondrial dysfunction which precedes reactive oxygen species formation. In this mini review, we give an update of the classical pathways involving these mechanisms of neurodegeneration, the biochemical and molecular events that mediate or regulate DA neuronal vulnerability, and the role of PD-related gene products in modulating cellular responses to oxidative stress in the course of the neurodegenerative process.

9 September 2008 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
JOJose A. Obeso
Jose A. Obeso
MRMaría Cruz Rodríguez-Oroz
María Cruz Rodríguez-Oroz
BBBeatriz Benitez-Temiño
Beatriz Benitez-Temiño
JBJavier Blesa
Javier Blesa
JGJorge Guridi
Jorge Guridi
MRManuel Rodriguez
Manuel Rodriguez

16 November 2013 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
Ariadna RecasensAriadna Recasens
Ariadna Recasens
BDBenjamin DEHAY
Benjamin DEHAY
JBJordi Bové
Jordi Bové
ICIria Carballo‐Carbajal
Iria Carballo‐Carbajal
SDSandra Dovero
Sandra Dovero
MVMiquel Vila
Miquel Vila

15 December 2014 in Frontiers in Neuroanatomy
Verified
Journal Article
Open access
PDF file
JBJavier Blesa
Javier Blesa
SPSerge Przedborski
Serge Przedborski
Parkinson's disease (PD) is a neurodegenerative disorder that affects about 1.5% of the global population over 65 years of age. A hallmark feature of PD is the degeneration of the dopamine (DA) neurons in the substantia nigra pars compacta (SNc) and the consequent striatal DA deficiency. Yet, the pathogenesis of PD remains unclear. Despite tremendous growth in recent years in our knowledge of the molecular basis of PD and the molecular pathways of cell death, important questions remain, such as: 1) why are SNc cells especially vulnerable; 2) which mechanisms underlie progressive SNc cell loss; and 3) what do Lewy bodies or α-synuclein reveal about disease progression. Understanding the variable vulnerability of the dopaminergic neurons from the midbrain and the mechanisms whereby pathology becomes widespread are some of the primary objectives of research in PD. Animal models are the best tools to study the pathogenesis of PD. The identification of PD-related genes has led to the development of genetic PD models as an alternative to the classical toxin-based ones, but does the dopaminergic neuronal loss in actual animal models adequately recapitulate that of the human disease? The selection of a particular animal model is very important for the specific goals of the different experiments. In this review, we provide a summary of our current knowledge about the different in vivo models of PD that are used in relation to the vulnerability of the dopaminergic neurons in the midbrain in the pathogenesis of PD.

1 January 2012 in Journal of Biomedicine and Biotechnology
Verified
Journal Article
Open access
PDF file
JBJavier Blesa
Javier Blesa
SPSudarshan Phani
Sudarshan Phani
VJVernice Jackson-Lewis
Vernice Jackson-Lewis
SPSerge Przedborski
Serge Przedborski
Neurological disorders can be modeled in animals so as to recreate specific pathogenic events and behavioral outcomes. Parkinson’s Disease (PD) is the second most common neurodegenerative disease of an aging population, and although there have been several significant findings about the PD disease process, much of this process still remains a mystery. Breakthroughs in the last two decades using animal models have offered insights into the understanding of the PD disease process, its etiology, pathology, and molecular mechanisms. Furthermore, while cellular models have helped to identify specific events, animal models, both toxic and genetic, have replicated almost all of the hallmarks of PD and are useful for testing new neuroprotective or neurorestorative strategies. Moreover, significant advances in the modeling of additional PD features have come to light in both classic and newer models. In this review, we try to provide an updated summary of the main characteristics of these models as well as the strengths and weaknesses of what we believe to be the most popular PD animal models. These models include those produced by 6-hydroxydopamine (6-OHDA), 1-methyl-1,2,3,6-tetrahydropiridine (MPTP), rotenone, and paraquat, as well as several genetic models like those related to alpha-synuclein, PINK1, Parkin and LRRK2 alterations.

1 December 2017 in Experimental Neurology
Verified
Journal Article
Closed access
JBJavier Blesa
Javier Blesa
ITInés Trigo-Damas
Inés Trigo-Damas
MDMichele Dileone
Michele Dileone
NRNatalia Lopez-Gonzalez del Rey
Natalia Lopez-Gonzalez del Rey
LHLedia F. Hernandez
Ledia F. Hernandez
JOJosé A. Obeso
José A. Obeso